Lunai Bioworks

Hello! 👋 We’re Lunai Bioworks. Decoding life. Discovering cures. Our AI-powered phenomics platform captures disease in motion, decoding biology at scale to bring clarity to complexity.

At BioSymetrics, the Phenograph is part of @lunaibioworks' platform for connecting prediction to proof. Together with Augusta and zebrafish-based in vivo modeling, it links translation and validation in one workflow. #DrugDiscovery #ArtificialIntelligence #TranslationalScience

Read the press release: ir.lunaibioworks.com/news/news-deta…. Learn more at lunaibioworks.com.

Together, these capabilities are intended to support multi-agent strategies, meaning combinations of therapeutic agents with different mechanisms of action, and more targeted development with Augusta.

Lunai Bioworks has completed and expanded our previously announced $20M CNS-focused transaction through the NeuroBridge IP acquisition, adding complementary brain-delivery capabilities to our CNS platform. #CNS #DrugDelivery #Neuroscience

BioSymetrics (a @lunaibioworks company) signed a non-binding Letter of Intent with Geneial to build trial-ready cohorts from patient-led data, starting in select rare neurodevelopmental disorders. #RareDisease #ClinicalTrials #PrecisionMedicine

BioSymetrics (a @lunaibioworks company) is at the AWS Life Sciences Symposium in NYC today (April 14) at the Javits Center. If you’re here too, let’s connect. #LifeSciences #DrugDiscovery #AWS

BioSymetrics (a @lunaibioworks company) is heading to the AWS Life Sciences Symposium in NYC on Tuesday, April 14 at the Javits Center. If you’re attending, let’s connect. #LifeSciences #DrugDiscovery #AWS

BioSymetrics (a @lunaibioworks company) has entered a commercial defense collaboration to build an AI-enabled platform for chemical threat assessment. Work is underway, with additional opportunities under discussion. #Biodefense #ChemicalThreats #MachineLearning

Learn more about Lunai Bioworks: lunaibioworks.com

Read the press release: ir.lunaibioworks.com/news/news-deta…

Lunai Bioworks (NASDAQ: LNAI) has announced a $20M transaction to acquire blood-brain barrier (BBB) delivery technology and CNS Alzheimer’s drug assets from the Clemann Group. BBB delivery is a major bottleneck in CNS drug development. #Alzheimers #CNS #BloodBrainBarrier

BioSymetrics (a @lunaibioworks company; NASDAQ: LNAI) has launched the Pathfinder Consortium, a national academic-industry alliance designed to accelerate medical countermeasures for emerging chemical threats. #Biodefense #MedicalCountermeasures #AIforDrugDiscovery

Want to meet at PMWC? Contact us here: lunaibioworks.com/contact

We’re sharing how Augusta couples predictive AI with high-throughput in vivo validation to help improve translational confidence for complex diseases, including neurology, alongside updates from our biodefense work.

Lunai Bioworks has landed at @PMWCintl 2026 in Santa Clara (Mar 4–6). If you’re working on neurology programs and care about translation-first drug discovery, we’d love to connect. #PMWC2026 #DrugDiscovery #Biodefense